Complizen Learn

Software as a Medical Device (SaMD) is software intended for one or more medical purposes that performs those purposes without being part of a hardware medical device (IMDRF definition used by FDA). SaMD typically runs on general-purpose platforms like phones, tablets, PCs, or cloud servers. If your software’s intended use is to diagnose, treat, mitigate, cure, prevent disease, or drive clinical decision-making, it may be regulated as a medical device unless it fits an exclus

Quick answer: Your FDA medical device classification (Class I, II, or III) is based on risk and the controls needed to assure safety and effectiveness. You can usually find it by searching FDA’s Product Classification resources, then confirming the regulation number (21 CFR 862–892) and product code (3-letter code) that match your intended use and technology. FDA has classified over 1,700 generic device types across 16 medical specialty panels. Classification drives your like

FDA establishment registration tells FDA where medical devices are made or processed (for example manufacturing, sterilization, relabeling, repacking) and carries an annual establishment registration fee of $11,423 for FY2026. Device listing tells FDA which devices are associated with that establishment, and when applicable it includes the relevant premarket reference such as a 510(k), De Novo, PMA, or an exemption status. Annual registration must be submitted each year betwe

FDA can help you sell beyond America A lot of international manufacturers still ask the wrong question: “Is FDA clearance worth it if the U.S. is not our main market?” That is too narrow. Yes, the U.S. matters. It is still the world’s largest medical device market, with about 40% of global share . But for some manufacturers, the bigger value of FDA is not just access to America. It is what FDA helps you do outside America: sell in markets with stringent regulatory requiremn

FDA Additional Information (AI) requests flag deficiencies in a 510(k) during substantive review and place the submission on hold. The submitter has 180 calendar days from the date of the AI Request to provide a complete response, and FDA states no extensions beyond 180 days are granted. The most common AI Request themes typically include substantial equivalence gaps, missing or unclear test evidence, incomplete device description, software documentation issues, biocompatib

AI tools can speed up specific parts of FDA medical device regulatory work, especially first-pass predicate research, guidance discovery, requirements checklists, gap spotting, and first-draft writing. The biggest risk is accuracy: general-purpose LLMs can generate confident text with false facts or hallucinated citations, so you should treat them as drafting and research assistants, not as sources of truth. Specialized regulatory platforms like Complizen reduce verification

Biocompatibility testing evaluates whether a patient-contacting medical device could cause adverse biological responses. ISO 10993-1 provides a risk-management framework: categorize the device by nature of body contact (surface, external communicating, implant) and contact duration (limited ≤24 hours, prolonged >24 hours to 30 days, long-term >30 days), then justify the relevant biological endpoints based on the FDA/ISO tables and your risk assessment. Cytotoxicity, sensitiza

A medical device recall is a firm's removal or correction of a marketed device that violates FDA law or poses a health risk. FDA classifies recalls by severity: Class I (reasonable probability of serious adverse health consequences or death), Class II (temporary or medically reversible adverse health consequences), Class III (unlikely to cause adverse health consequences). Recalls are governed by 21 CFR Part 7, while corrections and removals reporting falls under 21 CFR Part

How Tariffs and Geopolitics Are Changing U.S. Market Entry for International Medical Device Manufacturers For years, regulatory strategy meant understanding the FDA. Guidance. Pathways. Testing requirements. That is no longer enough. Because increasingly, market access is being shaped by geopolitics, not just regulation. The Shift Regulatory and global strategy used to be separate. Now they are converging. The U.S. medical device market alone accounts for ~40% of global dema

International medical device manufacturers often run into the same avoidable U.S. market-entry mistakes: assuming CE-mark experience will translate cleanly to FDA, choosing the wrong predicate strategy, trying to reuse EU clinical data without reframing it for substantial equivalence, misunderstanding when a U.S. Agent is needed, missing U.S.-specific testing expectations, underestimating the burden of Additional Information requests, overlooking remaining QMSR gaps after ISO

Sometimes. FDA may accept clinical data generated outside the United States, including data first collected for CE-marking work, in a 510(k) submission, but only if the study is well designed, well conducted, compliant with FDA’s foreign clinical data requirements under 21 CFR 812.28, and relevant to the U.S. substantial-equivalence case. The key issue is not whether the data came from Europe. It is whether the study supports the predicate-based questions FDA is actually aski

Tariffs are usually discussed in terms of trade policy, manufacturing costs, and geopolitics. But in the global medical device industry, they may be doing something else entirely. They are quietly creating the next wave of companies entering the U.S. healthcare market. Across Southeast Asia and other emerging manufacturing hubs, medical device manufacturers that historically focused on contract production are beginning to ask a different question: What if we sold directly int

CE Mark and FDA 510(k) are separate regulatory pathways for medical device market access. CE Mark certification demonstrates compliance with the European Union Medical Device Regulation (EU MDR 2017/745), granting sales rights across 30 European Economic Area countries. FDA 510(k) clearance proves substantial equivalence to predicate devices under US regulations, enabling United States market access only. Key differences: CE Mark requires Notified Body certification for Class

Reduce medical device clinical trial costs by 40-60% through strategic FDA engagement and smart study design. The #1 cost saver: Pre-Sub meeting ($50K investment) clarifies whether FDA will accept single-arm vs RCT, smaller patient counts, or shorter followup—potentially saving $2M-$5M before you commit to trial design. Other high-impact strategies: use single-arm design when FDA accepts objective endpoints (cuts costs 40-50% vs RCT), optimize site count to 5-8 sites (vs 15-2

AI can speed up 510(k) predicate research by 70-80%, find relevant FDA guidance in minutes instead of hours, and organize evidence trails automatically. But AI cannot make regulatory strategy decisions, replace required testing, or take accountability for submission content. Best results: Use AI for research-heavy tasks (finding predicates, FDA guidance, standards), pair with regulatory consultant for strategy and review. Cost comparison: AI tools $200-$2K/month vs. consultan

FDA inspects medical device manufacturers to verify compliance with 21 CFR Part 820 quality system requirements , using a structured approach often associated with the QSIT inspection method. Inspections can be routine surveillance or for-cause , such as follow-up to significant complaints, recalls, or other risk signals. Plan 8–24 weeks to get inspection-ready by closing CAPA gaps, organizing DHF and DMR records, confirming complaint handling, and running a mock audit. Du

For most Class II medical devices cleared through the 510(k) pathway , companies should plan for multiple years from concept to commercial launch , not months. While every product is different, 18–36 months is a common planning range once design complexity, testing, and regulatory realities are accounted for. FDA does not publish end-to-end “time-to-market” timelines. Delays usually come from underestimating development effort, testing lead times, and regulatory iteration ,

FDA expects performance testing that demonstrates your device functions as intended and does not raise different questions of safety or effectiveness compared to your predicate. The scope of testing depends on device type, risk, and technological differences, but most 510(k)s include bench or performance testing , software validation where applicable , and biocompatibility assessment for patient-contacting components . This guide shows you exactly which tests FDA requires for

If FDA disagrees with your predicate choice, you'll get an Additional Information (AI) request or a Not Substantially Equivalent (NSE) determination. AI requests often add months and require either: (1) switching to a different predicate, (2) providing stronger substantial equivalence rationale, or (3) withdrawing and refiling. Not Substantially Equivalent (NSE) determination usually means you must submit new 510(k) with different predicate or pursue De Novo. This guide walks

Human Factors Engineering (HFE), also called usability engineering, is how FDA expects you to show that intended users can operate your device safely and effectively in the intended use environment, especially when use error could cause harm. For many higher-risk device types, FDA often expects human factors data in 510(k)s and PMAs, and it is common to see it in De Novo programs when the user interface drives risk. If you change a user interface in a way that can affect comp